

# Veröffentlichungen

## I. Originalarbeiten als Erstautor

1. **Trarbach T**, Przyborek M, Schleucher N, Heeger S, Lüpfer C, Vanhoefer U. Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. *Invest New Drugs*, 2012 31: 642-652
2. **Trarbach T**, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Dreys. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. *Invest New Drugs*, 2012 30: 1962-1971
3. **Trarbach T**, Moehler M, Heinemann V, Koehne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S. Phase II trial of matuzumab, a fully human agonistic monoclonal antibody that targets and activates the tumor necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1) in patients with refractory colorectal cancer. *Br J Cancer*, 2010 102: 506-512.
4. **Trarbach T**, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, Schmiegel W, Graeven U. Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Onkologie*, 2010 33: 89-93.
5. **Trarbach T**, Schneider A, Noppeney R, Novotny J, Moritz T, Dührsen U, Seeber S, Flasshove M. CD34-subpopulations and clonogenic progenitors in mobilized peripheral blood cells from patients with acute myeloid leukemia. *Tumordiagn. u. Ther*, 2010 31: 269-275.
6. **Trarbach T**, Greifenberg S, Bardenheuer W, Elmaagali A, Hirche H, Flasshove M, Seeber S, Moritz T. Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments. *Cytotherapy*, 2000 2: 429-438.
7. **Trarbach T**, Scheulen ME, Schröder J, Stuschke M, Seeber S, Schütte J. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcoma. *Tumordiagn. u. Ther*, 1997 18: 57-60.

## II. Originalarbeiten als Letztautor

1. Kaiser GM, Sotiropoulos GC, Sgourakis G, Bleck J, Baba HA, Beckebaum S, Gerken G, Paul A, **Trarbach T**. Surgical treatment of Klatskin tumor: liver resection versus transplantation. *Hepatogastroenterology*, 2010 57: 1337-1340.

## III. Originalarbeiten als Co-Autor

1. Kasper S, Reis H, Ziegler S, Nothdurft S, Mueller A, Goetz M, Wiesweg M, Phasue J, Ting S, Wieczorek S, Even A, Worm K, Pogorzelski M, Breitenbuecher S, Meiler J, Paul A, **Trarbach T**, Schmid KW, Breitenbuecher F, Schuler M. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. *Oncotarget* 2017 (Epub ahead of print).
2. Sehouli J, Tome O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, Chakerov R, Muallem MZ, Lux MP, **Trarbach T**, Gitsch G. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). *J Cancer Res Clin Oncol* 2017 142 (3): 541-550.
3. Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, **Trarbach T**, Marschner N, Schmoll HJ, Hinke A, Al-Batram SE, Arnold D. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. *Ann Oncol*, 2016 12: 2203-2210.
4. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO0207): a randomized, non-inferiority, open-label, phase 3 trial. *Lancet Oncol*, 2015 16(13): 1355-1369.
5. Folprecht G, Hamann S, Schütte K, **Trarbach T**, Stoehlmacher-Williams J, Ehninger G. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. *BMC*, 2014 14: 521.
6. Malka D, Cervera P, Foulon S, **Trarbach T**, de la Fouchardiere C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T,

Grenier J, Hammel P, Dollinger M, Andre T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; on behalf of the BINGO investigators. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomized, open-label, non-comparative phase 2 trial. *Lancet Oncol*, 2014 15(8): 819-828.

7. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehmacher-Williams J, Lang H, **Trarbach T**, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). *Ann Oncol*, 2014 25(5): 1018-1025.
8. Moehler M, Gockel I, Roessler HP, Arnold D, **Trarbach T**, Thomaidis T, Klautke G, Rödel C, Brenner B, Lang H, Galle PR, Schimanski CC, Schmidberger H. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. *BMC Cancer*, 2013 13: 75.
9. Kaiser GM, Paul A, Sgourakis G, Molmenti EP, Dechene A, **Trarbach T**, Stuschke M, Baba HA, Gerken G, Sotiropoulos GC. Novel prognostic scoring system after surgery for Klatskin tumor. *Am Surg*, 2013 79: 90-95.
10. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, **Trarbach T**, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. *Br J Cancer*, 2012 107: 1044-1050.
11. Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Köhler J, Paul A, **Trarbach T**, Schmid KW, Schuler M. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. *Oncogene*, 2012 32: 2873-2881.
12. Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, **Trarbach T**, Folprecht G, Meinhardt G, Lenz HJ. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus VEGFR inhibitor PTK787/ZK222584 (vatalanib). *Pharmacogenomics*, 2012 (Epub ahead of print).
13. Weisshardt P, **Trarbach T**, Dürig J, Paul A, Reis H, Tilki D, Miroshnik I, Ergün S, Klein D. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. *Histochem Cell Biol.*, 2012 137: 391-401.
14. Oezcelik A, Kaiser GM, Niebel W, Sleyman C, Treckmann JW, Sotiropoulos GC, Reinhardt R, **Trarbach T**, Malamutmann E, Paul A. Ten-year survival of

oesophageal cancer after an en-bloc esophagectomy. *J Surg Oncol*, 2012 105: 284-287.

15. Gencer D, Tauchert F, Keilhauer N, Al-batran SE, Stahl M, Oskay-Özcelik G, Hipp M, Leibbrand B, Prasnikar N, **Trarbach T**, Stoll C, van Kampen M, Hochhaus A, Lorenzen S, Hofheinz RD. Cancer patients and the Internet: a survey of the ‚Quality of Life‘ Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie‘. *Onkologie*, 2011 34: 435-440.
16. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, **Trarbach T**, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK222584 (vatalanib) antiangiogenic therapy. *Clin Cancer Res.*, 2011 17: 4892-4900.
17. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, **Trarbach T**, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; German Arbeitsgemeinschaft Internistische Onkologie (AIO). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. *Eur J Cancer*, 2011 47: 1511-1520.
18. Hecht JR, **Trarbach T**, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. *J Clin Oncol*, 2011 29: 1997-2003.
19. Welter S, Theegarten D, **Trarbach T**, Maletzki F, Stamatis G, Tötsch M. Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry. *J Thorac cardiovasc Surg.*, 2011 141: 1218-1222.
20. Moehler M, Mueller A, **Trarbach T**, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie. Cetuximab with irinotecan, folinic acid and 5-Fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. *Ann Oncol*, 2011 22: 1358-1366.
21. Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, Vernadakis S, **Trarbach T**, Paul A, Kaiser GM. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. *Eur J Med Res.*, 2010 15: 357-361.

22. Bockhorn M, Sotiropoulos G, Neuhaus J, Sgourakis G, Sheu SY, Molmenti E, Fingas C, **Trarbach T**, Frilling A, Broelsch CE. Prognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastases. *Int J Colorectal Dis.*, 2009 24: 845-850.
23. Lang H, Sotiropoulos GC, Sgourakis G, Schmitz KJ, Paul A, Hilgard P, Zöpf T, **Trarbach T**, Malago M, Baba HA, Broelsch CE. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. *J Am Coll Surg*, 2009 208: 218-228.
24. Oechsle K, Bokemeyer C, Hartmann JT, Budach W, **Trarbach T**, Stahl M, Boehlke I, Kollmannsberger C; German AIO/ARO/CAO group. Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. *J Cancer Res Clin Oncol.*, 2009 135: 163-172.
25. Bockhorn M, Frilling A, Frühauf NR, Neuhaus J, Molmenti E, **Trarbach T**, Malago M, Lang H, Broelsch CE. Survival of patients with synchronous and metachronous colorectal liver metastases—is there a difference? *J Gastrointest Surg* 2008, 12: 1399-1405.
26. Brauck K, Zenge MO, Vogt FM, Quick HH, Stock F, **Trarbach T**, Ladd ME, Barkhausen J. Feasibility of whole-body MR with T2- and T1-weighted real-time steady-state free precession sequences during continuous table movement to depict metastases. *Radiology*, 2008 246: 910-916.
27. Grammatikos G, Teichgräber V, Carpinteiro A, **Trarbach T**, Weller M, Hengge UR, Gulbins E. Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. *Antioxid Redox Signal.*, 2007 9: 1449-1456.
28. Dumitru CA, Carpinteiro A, **Trarbach T**, Hengge UR, Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. *Apoptosis* 2007, 12: 1533-1541.
29. Thomas AL, **Trarbach T**, Bartel C, Laurent D, Henry A, Poethig M, Wang J, Masson E, Steward W, Vanhoefer U, Wiedenmann B. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. *Ann Oncol*, 2007 18: 782-788.
30. Ebeling P, Bach P, Sorg U, Schneider A, **Trarbach T**, Dilloo D, Hanenberg H, Niesert S, Seeber S, Moritz T, Flasshove M. Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency mouse repopulating cells. *J Cancer Res Clin Oncol*, 2007 133: 199-209.

31. Schleucher N, **Trarbach T**, Stahl M, Eberhardt W, Wilke H, Pöttgen C, Seeber S, Vanhoefer U. Phase I study of weekly schedule of infusional 5-fluorouracil/leucovorin and irinotecan in combination with escalating doses of biweekly cisplatin as first-line chemotherapy for advanced gastric cancer. *Tumordiagn. u. Ther*, 2006 27: 255-258.
32. Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke H, Schleicher J, Vanhoefer U, Jehle EC, Oechsle K, **Trarbach T**, Oehlke I, Kanz L, Hartmann JT, Bokemeyer C. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. *Ann Oncol*, 2005 22: 175-184.
33. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, **Trarbach T**, Seeber S, Harstrick A, Baselga J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. *J Clin Oncol*, 2004 22: 175-184.
34. Bauer S, Hartung J, Gauler T, Gocke P, **Trarbach T**, Flasshove M, Nowrousian MR, Bojko P, Hense J, Seeber S, Schütte J. Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma. *Tumordiagn. u. Ther*, 2002 23: 219-224.

#### IV. Übersichten/Expert Opinions/Editorials

1. Livingstone E, **Trarbach T**, Zimmer L, Schuler M, Schadendorf D. Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology. *Dtsch Med Wochenschr.*, 2011 136: 39-44.
2. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, **Trarbach T**, Wollenberg A. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. *Ann Oncol*, 2011 22: 524-535.
3. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, **Trarbach T**, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P. Specific treatment situations in metastatic colorectal cancer. *Onkologie*, 2010 33 Suppl 4: 8-18.
4. Reinacher-Schick A, Arnold D, **Trarbach T**, Ridwelski K, Bruch HP, Kirchner T, Kubicka S, Schmoll HJ. Adjuvant therapy in colon cancer. *Onkologie*, 2010 33 Suppl 4: 2-7.

5. **Trarbach T**, Schmoll HJ. Rectal cancer and synchronous metastases: resection of primary tumor or not ? *Gastroenterol Clin Biol*, 2009 33: 1098-1100.
6. Kubicka S, Geissler M, Bruch HP, **Trarbach T**. Laparoscopic surgery and adjuvant therapy for colon cancer. *Onkologie*, 2009 32 Suppl 2: 3-6.
7. Lordick F, Ridwelski K, Al-Batran SE, **Trarbach T**, Schlag PM, Piso P. Treatment of gastric cancer. *Onkologie*, 2008 31 Suppl 5: 32-39.
8. **Trarbach T**, Kubicka S, Hacker U, Ridwelski K, Reinacher-Schick A. Adjuvant therapy of colon carcinoma. *Onkologie*, 2008 31 Suppl 5: 19-23.
9. Sauer R, Tannapfel A, Rödel C, Hölscher AH, Fietkau R, Vanhoefer U, **Trarbach T**. Die Therapie des Rektumkarzinoms. *Onkologie*, 2007 30 Suppl 2: 18-22.